Table 2.
Allelic Frequency of BRAF Mutations in Thyroid Cancers
Tumor Type | Specimen Type | Mutation Type | BRAF Mutant Allele Frequency | BRAF Mutation Frequencya | Concurrent Mutations (Allele Frequency) |
---|---|---|---|---|---|
PTC | FFPE | BRAF V600E | 36% | 72% | |
PTC | FRZ | BRAF V600E | 44% | 88% | |
PTC | FRZ | BRAF V600E | 43% | 86% | |
PTC | FRZ | BRAF V600E | 39% | 78% | |
PTC | FFPE | BRAF V600E | 37% | 74% | TP53 (40%) |
PTC | FRZ | BRAF V600E | 36% | 72% | |
PTC | FRZ | BRAF V600E | 34% | 68% | |
PTC | FRZ | BRAF V600E | 31% | 62% | |
PTC | FFPE | BRAF V600E | 29% | 58% | |
PTC | FFPE | BRAF V600E | 22% | 44% | |
PTC | FFPE | BRAF V600E | 18% | 36% | |
PTC | FFPE | BRAF V600E | 35% | 70% | |
PTC | FRZ | BRAF V600_R603 delVKSR, T599I | 42% | 84% | |
PTC | FFPE | BRAF V600E | 39% | 78% | PIK3CA (38%), TP53 (31%) |
PMC (PTC) | FNA | BRAF V600E | 18% | 36% | |
FLUS (PTC) | FNA | BRAF V600E | 17% | 34% | |
PTC, FV | FFPE | BRAF K601E | 30% | 60% | |
PTC, FV | FFPE | BRAF V600E | 29% | 58% | |
PDC | FRZ | BRAF V600E | 48% | 96% | |
ATC | FRZ | BRAF V600E | 20% | 40% | |
ATC | FFPE | BRAF V600E | 23% | 46% | TP53 (60%) |
ATC | FFPE | BRAF V600E | 34% | 68% | PIK3CA (16%) |
ATC | FFPE | BRAF K601E | 38% | 76% | |
ATC | FFPE | BRAF V600E | 5.2% | 10.4% | TP53 (4.9%) |
ATC | FRZ | BRAF V600E | 5.9% | 11.8% | TP53 (8.8%); PIK3CA (11%) |
ATC | FRZ | BRAF V600E | 8.0% | 16.0% |
Abbreviations: FLUS, follicular lesion of undetermined significance on FNA; FRZ, frozen tissue; PMC, positive for malignant cells on FNA; FV, follicular variant.
Based on the assumption that the mutation is heterozygous.